John K. Bakewell's Insider Trades & SAST Disclosures
John K. Bakewell's most recent trade in Treace Medical Concepts Inc was a trade of 23,917 Common Stock done . Disclosure was reported to the exchange on May 20, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern John K. Bakewell.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Treace Medical Concepts Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 23,917 | 174,056 | - | 0 | Common Stock | |
| Treace Medical Concepts Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 33,260 | 33,260 | - | - | Stock Option (Right to Buy) | |
| Treace Medical Concepts Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 15,091 | 150,139 | - | 0 | Common Stock | |
| Treace Medical Concepts Inc | John K. Bakewell | Director | Purchase of securities on an exchange or from another person at price $ 4.57 per share. | 10 May 2024 | 130,000 | 135,048 | - | 4.6 | 594,620 | Common Stock |
| Neuronetics Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 36,364 | 114,352 (0%) | 0% | - | Common Stock | |
| Neuronetics Inc | John K. Bakewell | Director | Sale of securities on an exchange or to another person at price $ 2.70 per share. | 24 May 2023 | 14,400 | 77,988 (0%) | 0% | 2.7 | 38,880 | Common Stock |
| Treace Medical Concepts Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 6,305 | 6,305 | - | - | Stock Option (Right to Buy) | |
| Treace Medical Concepts Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 2,753 | 5,048 | - | 0 | Common Stock | |
| Neuronetics Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 38,910 | 92,388 (0%) | 0% | - | Common Stock | |
| Treace Medical Concepts Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 16,625 | 16,625 | - | - | Stock Option (Right to Buy) | |
| Treace Medical Concepts Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 2,295 | 2,295 | - | 0 | Common Stock | |
| Neuronetics Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,137 | 49,428 (0%) | 0% | - | Common Stock | |
| Treace Medical Concepts Inc | John K. Bakewell | SVP, Research & Development | 27 Apr 2021 | 342,300 | 342,300 | - | - | Common Stock | ||
| Treace Medical Concepts Inc | John K. Bakewell | SVP, Research & Development | 27 Apr 2021 | 342,300 | 0 | - | - | Series A Preferred Stock | ||
| Treace Medical Concepts Inc | John K. Bakewell | SVP, Research & Development | Other type of transaction at price $ 0.00 per share. | 27 Apr 2021 | 7,925 | 342,300 | - | - | Series A Preferred Stock | |
| Treace Medical Concepts Inc | John K. Bakewell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2021 | 21,240 | 21,240 | - | - | Stock Option Right to Buy | |
| Neuronetics Inc | John K. Bakewell | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 12,291 | 42,291 (0%) | 0% | - | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges